Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding
Others
Ratios

Applied Therapeutics (APLT) Non Operating Income (2023 - 2025)

Historic Non Operating Income for Applied Therapeutics (APLT) over the last 3 years, with Q3 2025 value amounting to -$2.2 million.

  • Applied Therapeutics' Non Operating Income rose 9425.45% to -$2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $80.3 million, marking a year-over-year increase of 18446.64%. This contributed to the annual value of -$1.3 million for FY2024, which is 9760.09% up from last year.
  • Per Applied Therapeutics' latest filing, its Non Operating Income stood at -$2.2 million for Q3 2025, which was up 9425.45% from $1.8 million recorded in Q2 2025.
  • Applied Therapeutics' 5-year Non Operating Income high stood at $77.0 million for Q4 2024, and its period low was -$62.8 million during Q1 2024.
  • Over the past 3 years, Applied Therapeutics' median Non Operating Income value was -$2.2 million (recorded in 2025), while the average stood at -$4.8 million.
  • Data for Applied Therapeutics' Non Operating Income shows a peak YoY increase of 56205.39% (in 2024) and a maximum YoY decrease of 881636.62% (in 2024) over the last 5 years.
  • Applied Therapeutics' Non Operating Income (Quarter) stood at -$16.7 million in 2023, then soared by 562.05% to $77.0 million in 2024, then plummeted by 102.9% to -$2.2 million in 2025.
  • Its last three reported values are -$2.2 million in Q3 2025, $1.8 million for Q2 2025, and $3.7 million during Q1 2025.